Multidisciplinary Clinical Case Study

Mycobacterium fortuitum Meningitis: Approach to Lumboperitoneal Shunt Infection

Authors: Jack Zakrzewski, BS, Kimberly Hu, BS, Brandon L. Neisewander, BA, Darian R. Esfahani, MD, MPH, Abhiraj D. Bhimani, BS, Harsh P. Shah, MD, Dafer W. Haddadin, MD, Ankit I. Mehta, MD

Abstract

Mycobacterium fortuitum is a rare, opportunistic pathogen most frequently contracted through contact with a contaminated source. An immunocompetent 26-year-old female patient presented to our institution with an infected lumboperitoneal (LP) shunt presenting as continued nonhealing wounds. After multiple debridements, shunt revisions, and wound closure failures, infectious disease specialists were consulted. The wound cultures returned positive for M. fortuitum and the shunt was removed. Cerebrospinal fluid studies revealed significant pleocytosis with normal opening pressure, and the patient was diagnosed as having secondary meningitis. After shunt removal, the patient was treated with intravenous and oral antibiotics, resulting in infection resolution. Five months later, a new LP shunt was placed without infection recurrence. Although M. fortuitum was previously reported in neurosurgical patients with ventriculoperitoneal shunts, which are summarized here, to date this is the first case in the literature of M. fortuitum meningitis from an LP shunt. This case demonstrates the importance of clinicians considering uncommon and slow-growing pathogens, as well as consulting infectious disease specialists for patients with persistent, unexplained infections.
Posted in: Neurology17 Central Nervous System (CNS) Infections1

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Han XY, Dé I, Jacobson KL. Rapidly growing mycobacteria: clinical and microbiologic studies of 115 cases. Am J Clin Pathol 2007;128:612-621.
2. Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. New York:Elsevier Health Sciences;2015.
3. Wagner D, Young L. Nontuberculous mycobacterial infections: a clinical review. Infection 2004;32:257-270.
4. Mayo Clinic. Pseudotumor cerebri. http://www.mayoclinic.org/diseases-conditions/pseudotumor-cerebri/home/ovc-20249919. Published 2017. Accessed January 19, 2019.
5. National Institute of Neurological Disorders and Stroke. Pseudotumor cerebri information page. https://www.ninds.nih.gov/Disorders/All-Disorders/Pseudotumor-Cerebri-Information-Page/2840/organizations/1225. Accessed January 28, 2019.
6. Hainline C, Rucker JC, Balcer LJ. Current concepts in pseudotumor cerebri. Curr Opin Neurol 2016;29:84-93.
7. Johnston I, Kollar C, Dunkley S, et al. Cranial venous outflow obstruction in the pseudotumour syndrome: incidence, nature and relevance. J Clin Neurosci 2002;9:273-278.
8. Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012;83:488-494.
9. Sugerman HJ, Felton WL 3rd, Sismanis A, et al. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg 1999;229:634-642.
10. Corbett JJ, Thompson HS. The rational management of idiopathic intracranial hypertension. Arch Neurol 1989;46:1049-1051.
11. McGirt MJ, Zaas A, Fuchs HE, et al. Risk factors for pediatric ventriculoperitoneal shunt infection and predictors of infectious pathogens. Clin Infect Dis 2003;36:858-862.
12. Midani S, Rathore MH. Mycobacterium fortuitum infection of ventriculoperitoneal shunt. South Med J 1999;92:705-707.
13. Cadena G, Wiedeman J, Boggan JE. Ventriculoperitoneal shunt infection with Mycobacterium fortuitum : a rare offending organism. J Neurosurg Pediatr 2014;14:704-707.
14. Chan KH, Mann KS, Seto WH. Infection of a shunt by Mycobacterium fortuitum: case report. Neurosurgery 1991;29:472-474.
15. Aliabadi H, Osenbach RK. Intrathecal drug delivery device infection and meningitis due to Mycobacterium fortuitum : a case report. Neuromodulation 2008;11:311-314.
16. Madaras-Kelly KJ, DeMasters TA, Stevens DL. Mycobacterium fortuitum meningitis associated with an epidural catheter: case report and a review of the literature. Pharmacotherapy 1999;19:661-666.
17. Hand WL, Sanford JP. Mycobacterium fortuitum a human pathogen. Ann Intern Med 1970;73:971-977.
18. Smith E. Mycobacterium fortuitum spinal infection: case report. Pathology 1976;8:289-292.
19. Santamaria-Jauregui J, Sanz-Hospital J, Berenguer J, et al. Meningitis caused by Mycobacterium fortuitum. Am Rev Respir Dis 1984;130:136-137.
20. Tankhiwale SS, Katkar VJ. Subdural empyma due to Mycobacterium fortuitum in a non-HIV patient. Indian J Med Microbiol 2014;32:446-448.
21. Conen A, Walti LN, Merlo A, et al. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin Infect Dis 2008;47:73-82.
22. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991;114(Pt 1A):155-180.
23. Wall M, Kupersmith MJ, Kieburtz KD, et al. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 2014;71:693-701.
24. Falkinham JO 3rd. Nontuberculous mycobacteria in the environment. Clin Chest Med 2002;23:529-551.
25. Patwardhan RV, Nanda A. Implanted ventricular shunts in the United States: the billion-dollar-a-year cost of hydrocephalus treatment. Neurosurgery 2005;56:139-145.
26. Jacob CN, Henein SS, Heurich AE, et al. Nontuberculous mycobacterial infection of the central nervous system in patients with AIDS. South Med J 1993;86:638-640.
27. Serra C, Loi G, Saddi B, et al. Unusual clinical presentation of Mycobacterium fortuitum infection in an immunocompetent woman. J Clin Microbiol 2007;45:1663-1665.
28. Olsen MA, Mayfield J, Lauryssen C, et al. Risk factors for surgical site infection in spinal surgery. J Neurosurg 2003;98(2 suppl):149-155.
29. Tanaka S, Inoue S, Isoda F, et al. Impaired immunity in obesity: suppressed but reversible lymphocyte responsiveness. Int J Obes Relat Metab Disord 1993;17:631-636.
30. Leong KS, Wilding JP. Obesity and diabetes. Baillieres Best Pract Res Clin Endocrinol Metab 1999;13:221-237.
31. Kiselar JG, Wang X, Dubyak GR, et al. Modification of β-defensin-2 by dicarbonyls methylglyoxal and glyoxal inhibits antibacterial and chemotactic function in vitro. PLoS One 2015;10:e0130533.
32. Wallace RJ, Jr Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae : importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992;166:405-412.
33. Stone M, Wallace R, Swenson J, et al. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics. Antimicrob Agents Chemother 1983;24:486-493.
34. Swenson JM, Wallace R, Silcox V, et al. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985;28:807-811.
35. Brown BA, Wallace RJ, Jr Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae -like organisms. Antimicrob Agents Chemother 1992;36:180-184.
36. Wallace RJ, Jr Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991;35:773-775.
37. Wallace RJ, Jr Bedsole G, Sumter G, et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 1990;34:65-70.
38. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
39. Maurer FP, Castelberg C, Quiblier C, et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J Antimicrob Chemother 2014;69:1559-1563.
40. Griffith D. Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum. https://www.uptodate.com/contents/rapidly-growing-mycobacterial-infections-mycobacteria-abscessus-chelonae-and-fortuitum. Accessed January 28, 2019.
41. Wallace RJ, Jr Swenson JM, Silcox VA, et al. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985;152:500-514.
42. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999;27:97-134, 196.
43. Anderson DJ, Podgorny K, Berrí-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35(suppl 2):S66-S88.